Ophiomics secures €1M in Seed Round as part of an EIC accelerator award. Funding round will support regulatory compliance and clinical validation
Lisbon, June 9th, 2021 – Ophiomics, a R&D biotechnology and AI company based in Lisbon, Portugal, today announced it raised seed capital of 1M€ from the EIC Fund complementing the EIC Accelerator Grant previously awarded to the company.
Ophiomics mission is to reduce the number of lives lost to liver cancer by contributing to its early detection and developing tools that select the right treatment for right patient, focusing on curative treatments.
This seed round follows earlier investment from the Germano de Sousa Group and the EIC Accelerator Grant and will support the regulatory and clinical validation of HepatoPredict and its market readiness by 2022. HepatoPredict is a gene expression signature and decision algorithm to select liver cancer patients for curative surgical procedures.
“This funding is another step in making HepatoPredict a global success, allowing us to potentially save thousands of lives by selecting the right liver cancer patients for liver transplantation and resection. It will further support the continued development of our portfolio of products towards a series A round sometime within the next 24 months “ says José Leal, CEO of Ophiomics.
“ We are proud to help Ophiomics to scale up. The EIC Fund supports this biotech company developing HepatoPredict, a decision tool for Liver Transplantation based on molecular signature” said Laura González-Estéfani, EIC Fund Investment Committee member
Ophiomics is a Biotech company developing new products and services integrating machine learning and genomics in support of diagnostic, prognostic, pharmacogenomics, and clinical follow up in liver cancer. We are based in Lisbon, Portugal, at the LISPOLIS incubator, close to multiple small and large companies focusing on human health technologies. Ophiomics was founded and is managed by José Leal and Joana Vaz, specialists in Bioinformatics and in Genomics, respectively. They have worked together for close to a decade, as academic researchers, establishing a clinical services laboratory focusing on oncogenomics, and now developing the next generation of products that will disrupt the way we manage liver cancer.
About the EIC Fund
Established in June 2020, the European Innovation Council Fund (EIC Fund) is a breakthrough initiative of the European Commission to make direct equity and quasi-equity investments (between €500.000 and €15 million) in European high impact and deep tech start-ups and scale ups. The EIC Fund provides patient capital and invests in companies from any sector, across all EU countries and countries associated to Horizon 2020.
The EIC Fund aims to fill a critical financing gap and its main purpose is not to maximise financial investment returns, but to have a high impact by accompanying companies with and disruptive technologies in their growth. Its objective is to crowd in market players, further sharing risks by building a large network of capital providers and strategic partners suitable for co-investments and follow on funding.
The Fund pays particular attention to empower and support female founders as well as contributing to reduce the innovation divide among EU countries